The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance
- 22 November 2013
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 32 (1) , 47-61
Abstract
Structural uncertainty relates to differences in model structure and parameterization. For many published health economic analyses in oncology, substantial differences in model structure exist, leading to differences in analysis outcomes and potentially impacting decision-making processes. The objectives of this analysis were (1) to identify differences in model structure and parameterization for cost-effectiveness analyses (CEAs) comparing tamoxifen and anastrazole for adjuvant breast cancer (ABC) treatment; and (2) to quantify the impact of these differences on analysis outcome metrics.Keywords
This publication has 54 references indexed in Scilit:
- Population pharmacokinetic–pharmacodynamic analysis for eribulin mesilate‐associated neutropeniaBritish Journal of Clinical Pharmacology, 2013
- Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancerAmerican Journal of Health-System Pharmacy, 2011
- A Framework for Addressing Structural Uncertainty in Decision ModelsMedical Decision Making, 2011
- Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast CancerPharmacoEconomics, 2008
- Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trialBritish Journal of Cancer, 2007
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trialBreast Cancer Research and Treatment, 2007
- Aromatase Inhibitors in Breast CancerPharmacoEconomics, 2006
- Prognostic and Predictive Factors in Early-Stage Breast CancerThe Oncologist, 2004
- An Introduction to Markov Modelling for Economic EvaluationPharmacoEconomics, 1998